Randox Laboratories has launched the Evidence Multistat - a desktop biochip analyser that offers up to eight cardiac results within 20 minutes.
The technology ensures the accuracy of a commercial laboratory analyser within the accident and emergency department, delivering benefits for patients with chest pains by rapidly identifying risk and enabling accurate clinical decisions.
With some blood biomarkers only detectable for six hours after a heart attack, patients presenting with early symptoms are often missed.
The Evidence Multistat will ultimately save patient lives by giving accurate and timely diagnosis when time is at a premium.
The Evidence Multistat is based upon the biochip technology from Randox.
It also offers an array for drugs of abuse with arrays for stroke, metabolic syndrome, cancer, fertility disorders, thyroid disorders, synthetic steroids and additional drugs of abuse currently in development.
The system is suitable for a variety of point-of-patient environments including emergency departments, cardiac units, doctor surgeries, forensic units, rehab units and employee drug-screening centres.
The technology offers fully automated pipetting, incubation, washing, imaging and report generation ensuring that the Multistat can be used by non-technical staff.
User-friendly touch-screen Windows-based software also ensures little or no training is required.
Randox has developed a comprehensive test menu that can work with a range of sample matrix including urine and serum, with plasma and whole blood currently in development.
The Cardiac Arrays includes CK-MB, FABP, myoglobin and cardiac troponin, while the Drugs of Abuse Array includes multiple analytes such as amphetamine, barbiturates, benzadiazepine, cannabinoids and cocaine.
